OTCMKTS:ENZN Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis $0.10 +0.01 (+16.96%) As of 05/2/2025 10:56 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enzon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.08▼$0.1050-Day Range$0.09▼$0.1252-Week Range$0.07▼$0.24Volume666 shsAverage Volume63,785 shsMarket Capitalization$7.42 millionP/E Ratio10.01Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Read More… Receive ENZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENZN Stock News HeadlinesEnzon Pharmaceuticals Expands Board and Forms Strategic CommitteeJanuary 10, 2025 | tipranks.comUS Penny Stocks Spotlight: Enzon Pharmaceuticals And 2 More To ConsiderDecember 13, 2024 | finance.yahoo.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.May 4, 2025 | Altimetry (Ad)Enzon Pharmaceuticals Inc ENZNNovember 8, 2023 | morningstar.comOKYO Pharma Limited (OK10.F)October 25, 2023 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. Common Stock (REGN)July 30, 2023 | nasdaq.comEnzon Stock Hits New 52-Week Low (ENZN)March 26, 2023 | thestreet.comIbnsina Pharma Co (ISPH)March 20, 2023 | investing.comSee More Headlines ENZN Stock Analysis - Frequently Asked Questions How have ENZN shares performed this year? Enzon Pharmaceuticals' stock was trading at $0.1561 at the start of the year. Since then, ENZN shares have decreased by 35.9% and is now trading at $0.10. View the best growth stocks for 2025 here. How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) posted its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.01) earnings per share for the quarter. How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX). Company Calendar Last Earnings4/30/2020Today5/04/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CIK727510 Webwww.enzon.com Phone(732) 980-4500Fax732-980-4585EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio10.01 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.37 million Net MarginsN/A Pretax Margin5,103.85% Return on Equity48.32% Return on Assets3.22% Debt Debt-to-Equity RatioN/A Current Ratio107.24 Quick Ratio107.24 Sales & Book Value Annual Sales$30,000.00 Price / Sales247.38 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares74,215,000Free Float73,918,000Market Cap$7.42 million OptionableNot Optionable Beta0.23 Social Links Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:ENZN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enzon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.